ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
Hospital Beatriz Ângelo · Humanitas University · +50 more institutions
Abstract
Crohn’s disease [CD] is a chronic inflammatory bowel disease [IBD] that can result in progressive bowel damage and disability1. CD can affect individuals of any age, from children to the elderly, 2, 3 and may cause significant morbidity and impact on quality of life. Up to one-third of patients present with complicated behaviour [strictures, fistula, or abscesses] at diagnosis4. Most patients over time will develop a complication, with roughly 50% of patients requiring surgery within 10 years of diagnosis5-7. As the precise aetiology of CD remains unknown, a curative therapy is not yet available8. Several agents are available for the medical treatment of CD. Medical agents include mesalazine [5-ASA], locally…
Citation impact
- FWCI
- 90.50
- Percentile
- 100%
- References
- 168
Authors
46- JTJoana Torres
Hospital Beatriz Ângelo
- SBStefanos Bonovas
Humanitas University
- GDGlen Doherty
University College Dublin, St. Vincent's University Hospital
- TKTorsten Kucharzik
Klinikum Lüneburg
- JPJavier P. Gisbert
Hospital Universitario de La Princesa, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Universidad Autónoma de Madrid
Topics & keywords
- Medicine
- Crohn's disease
- Intensive care medicine
- Inflammatory bowel disease
- Disease
- Infliximab
- Internal medicine
- Good health and well-being